Company Overview

JFL Life Sciences Limited, initially incorporated as JFL Life Sciences Private Limited on April 25, 2010, by Promoter and Director Mr. Smiral Patel, transitioned from a Private Limited to a Public Limited Company on March 3, 2022. Headquartered in Ahmedabad, Gujarat, the company is a prominent manufacturer and marketer of diverse pharmaceutical products for both domestic and international markets.

The company holds WHO-GMP certification and specializes in the manufacturing of Dry Powder Injectable Solid Oral Dosage Forms, including Beta Lactam and General products. JFL Life Sciences has established a strong reputation built on a commitment to quality manufacturing and stringent regulatory compliance.

Product Portfolio and Manufacturing Capabilities

JFL Life Sciences offers a comprehensive product range that includes:

- Dry powder injections

- Tablets & Capsules (B-Lactam and General)

- Oral Rehydration Solutions (ORS)

Notable beta-lactam dry powder injection products include Ampicillin Injection, Cefotaxime Sodium Injection (250 Mg), Cefazoline Sodium Injection, and Meropenem Injection (1 gm). Beta-lactam tablet and capsule offerings include Cefadroxil Tablets (500 mg) and Cefadroxil Capsules (500 mg).

The company's manufacturing operations are based in Kerala and Bavla, Ahmedabad, Gujarat, utilizing two leased manufacturing units. Currently, JFL Life Sciences operates at approximately 40% capacity utilization, indicating significant untapped potential for future growth and expansion by utilizing the remaining 60% capacity.

Global Market Presence and Regulatory Approvals

JFL Life Sciences has a wide market presence across PAN India and supplies its products to 10 developed and developing countries globally. The company's exports primarily target African, Middle Eastern, and CIS countries, often facilitated through merchant exporters.

JFL Life Sciences has successfully registered its products for manufacturing in various countries, including Kenya, Nigeria, Yemen, Cambodia, and Myanmar. Product registrations also extend to markets such as Ukraine, Uzbekistan, and Kazakhstan, creating a robust market moat.

Stock Exchange Listing and IPO Details

The Initial Public Offering (IPO) for JFL Life Sciences opened for bidding on August 25, 2022, and closed on August 30, 2022. The share allotment was finalized on Monday, September 5, 2022, with the shares listing on the NSE SME platform on September 8, 2022. The IPO price was set at ₹61 per share. The company is listed on the National Stock Exchange under the ticker symbol JFLLIFE.

Financial Performance and Market Metrics

As of the latest available data, JFL Life Sciences exhibits strong financial fundamentals:

- Market Capitalization: ₹65.00 Cr (as of 28th April 2025)

- Revenue: ₹82.0 Cr (FY25)

- Profit: ₹4.16 Cr (FY25)

- Reported FY25 Profit: ₹613.54 Lakhs (with unmodified audit opinion and bonus shares issued, as of 28 June 2025)

- P/E Ratio: 19.70

- P/B Ratio: 1.83

- 52-week High: ₹37.15

- 52-week Low: ₹12.33

Recent Developments and Corporate Actions

JFL Lifesciences Limited's stock saw a positive movement following key corporate announcements. The board declared a 2:1 bonus issue, with the record date set for September 24, 2024. Additionally, the Board of Directors recommended a final dividend of ₹0.25 per equity share (2.5%), subject to shareholder approval, as announced on August 2, 2024.

The company secured a significant order worth ₹11.95 Cr from the Brihanmumbai Municipal Corporation for injection supplies spanning 2025-27 (as of July 1, 2025), underscoring robust demand for its products in the institutional segment.

Promoter Holdings and Management

Promoter Holding stands at a significant 67.5%, reflecting strong management commitment to the business. The company's promoters are Smiral Ashwinkumar Patel and Tejal Smiral Patel. JFL Life Sciences is privately owned and characterized by its robust financial health. The top management is actively involved in daily operations, ensuring swift and effective decision-making processes.

Business Strategy and Competitive Advantages

JFL Life Sciences employs a sales strategy focused on bulk product sales to pharmaceutical marketers and traders, who then manage distribution to end-customers. The company emphasizes its strong environmental record and has developed robust Standard Operating Procedures (SOPs), establishing it as a highly system-driven organization.

JFL Life Sciences is positioned as a reliable manufacturer in the pharmaceutical industry due to its WHO-GMP certification, a diverse product portfolio, and an expanding global footprint. The company's strategic focus on Beta-Lactam products and dry powder injectables, coupled with its extensive regulatory approvals across multiple countries, provides a distinct competitive edge in the specialized pharmaceutical manufacturing sector.